运动、艾司西酞普兰或安慰剂对冠心病患者焦虑的影响:UNWIND随机临床试验
这项随机临床试验纳入128例稳定冠心病伴焦虑障碍或HADS-A≥8分的门诊患者,比较12周有氧运动、艾司西酞普兰(最高20 mg/d)与安慰剂对焦虑的疗效。艾司西酞普兰和运动均比安慰剂更降低HADS-A评分,艾司西酞普兰优于运动;三组冠心病风险生物标志物变化无显著差异。艾司西酞普兰治疗焦虑安全有效,运动效果不一致。
要点
- 艾司西酞普兰(最高20 mg/d)12周可安全有效降低冠心病患者焦虑症状。
- 有氧运动3次/周、70%-85%心率储备强度对焦虑的改善不如艾司西酞普兰稳定。
- 运动和艾司西酞普兰均未改善心率变异性等冠心病风险生物标志物。
核心结论
- 艾司西酞普兰治疗冠心病患者焦虑安全有效,运动对焦虑症状的改善效果不一致。
- 运动和艾司西酞普兰均未改善冠心病风险生物标志物,需进一步研究临床结局。
研究设计与样本
- 随机临床试验,2016年1月至2020年5月在美国一家三级教学医院开展。
- 纳入128例年龄>40岁、久坐、未接受精神健康治疗的稳定冠心病门诊患者,伴焦虑障碍诊断或HADS-A≥8分。
- 干预12周:有氧运动3次/周(70%-85%心率储备)、艾司西酞普兰(最高20 mg/d)或等效安慰剂。
主要发现
- 所有组冠心病生物标志物(心率变异性、压力反射敏感性、血流介导舒张)变化相似且幅度小,治疗组间无差异。
关键数值与推荐
- 主要结局为HADS-A评分;CHD生物标志物包括心率变异性、压力反射敏感性、血流介导舒张及24小时尿儿茶酚胺。
临床怎么用
- 对稳定冠心病伴焦虑障碍或HADS-A≥8分的患者,可考虑艾司西酞普兰(最高20 mg/d)改善焦虑,但需注意该研究未显示冠心病风险生物标志物获益。
- 运动可作为辅助手段,但其改善焦虑的效果不如艾司西酞普兰稳定。
局限性
- 样本量128例,女性仅37例(29%),结果外推需谨慎。
- 干预和随访12周,长期疗效与临床结局未评估。
- 原文未报告盲法、依从性及脱落情况等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anxiety is common among patients with coronary heart disease (CHD) and is associated with worse health outcomes; however, effective treatment for anxiety in patients with CHD is uncertain. OBJECTIVE: To determine whether exercise and escitalopram are better than placebo in reducing symptoms of anxiety as measured by the Hospital Anxiety and Depression-Anxiety Subscale (HADS-A) and in improving CHD risk biomarkers. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted between January 2016 and May 2020 in a tertiary care teaching hospital in the US and included 128 outpatients with stable CHD and a diagnosed anxiety disorder or a HADS-A score of 8 or higher who were older than 40 years, sedentary, and not currently receiving mental health treatment. INTERVENTIONS: Twelve weeks of aerobic exercise 3 times per week at an intensity of 70% to 85% heart rate reserve, escitalopram (up to 20 mg per day), or placebo pill equivalent. MAIN OUTCOMES AND MEASURES: The primary outcome was HADS-A score. CHD biomarkers included heart rate variability, baroreflex sensitivity, and flow-mediated dilation, along with 24-hour urinary catecholamines. RESULTS: The study included 128 participants. The mean (SD) age was 64.6 (9.6) years, and 37 participants (29%) were women. Participants randomized to the exercise group and escitalopram group reported greater reductions in HADS-A (exercise, -4.0; 95% CI, -4.7 to -3.2; escitalopram, -5.7; 95% CI, -6.4 to -5.0) compared with those randomized to placebo (-3.5; 95% CI, -4.5 to -2.4; P = .03); participants randomized to escitalopram reported less anxiety compared with those randomized to exercise (-1.67; 95% CI, -2.68 to -0.66; P = .002). Significant postintervention group differences in 24-hour urinary catecholamines were found (exercise z score = 0.05; 95% CI, -0.2 to 0.3; escitalopram z score = -0.24; 95% CI, -0.4 to 0; placebo z score = 0.36; 95% CI, 0 to 0.7), with greater reductions in the exercise group and escitalopram group compared with the placebo group (F1,127 = 4.93; P = .01) and greater reductions in the escitalopram group compared with the exercise group (F1,127 = 4.37; P = .04). All groups achieved comparable but small changes in CHD biomarkers, with no differences between treatment groups. CONCLUSIONS AND RELEVANCE: Treatment of anxiety with escitalopram was safe and effective for reducing anxiety in patients with CHD. However, the beneficial effects of exercise on anxiety symptoms were less consistent. Exercise and escitalopram did not improve CHD biomarkers of risk, which should prompt further investigation of these interventions on clinical outcomes in patients with anxiety and CHD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02516332.
引用
- Blumenthal JA, Smith PJ, Jiang W, et al. Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial. JAMA Psychiatry. 2021. PMID: 34406354. doi:10.1001/jamapsychiatry.2021.2236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。